



BIOTHERAPY

Macopharma,
Your **Cell**
Therapy / ECP
Partner

A **solution** for **each step** of your
cellular therapy process




BIO THERAPY

TISSUES

STEM CELLS

ORGANS

CORD BLOOD



BIO-BANKING



CELL CULTURE




PHOTOPHERESIS



TRANSPLANT



Treat patients



TRANSFUSION

INFUSION

BIO THERAPY

MASKS

MISSION STATEMENT

Mission: To provide customers in the fields of cell and tissue therapy, regenerative medicine and transplantation worldwide **high quality GMP single use** sterile closed systems to **collect, treat, expand and preserve** human regenerative cells, tissues and organs that consistently improve and **secure cellular therapy practices and clinical protocols**

Macopharma and ECP

HISTORICAL TIMELINE



**MACOGENIC
G1**



2001



2011

1990

2007


**MACOGENIC
G2**



Macogenic G2
09MG2000
C E 0450

METHOXYPYSORALEN 8-MOP
CSL1800XA
ANM PA: 18.07.10.100

UVA illumination bag
XUV18501a
C E 0450



XUV Bag




8MOP

**2015
100 MACOGENIC
WORLDWIDE**

Global presence


- Company presence in over 70 countries
 - Dedicated Photopheresis Sales and Maintenance Team in each EU-Country
 - 3 Centres of Excellence in Europe
-
- Macogenic is used in more than 20 countries, from South-America to North-East Asia
 - Close to 100 Macogenics have been installed worldwide, cumulating over 100,000 procedures



Increasing demand for Off-line techniques in EU*?

Users experience:

- “ Off-Line ECP makes it possible to work with performant therapeutic apheresis platforms that guaranty a high cell yield, high concentration of MNC's and low hematocrit ”
- “ Possibility of treating pediatric / low weight patients (<20 kg) ”
- “ Extra-corporeal volume is limited ”
- “ Cell collection equipment can be mutualized ”
- “ Quality controls and biological tests can easily be performed ”
- “ Off-Line ECP technique is cost-effective ”



*Except in France

Investing in the future...

- Investing in the technique to secure lab / clinical practices (New illumination kit in 2015)
- Investing in the manufacturing (Kits, Macogenic and 8Mop made in France)
- Investing in a dedicated team to promote and support ECP
- Investing in new therapeutic indications (3 clinical trials in Europe in 2015)
- Investing in improving treatment for paediatric patients



together with our partners, the medical community

THANK YOU